ArticleJournal of immunology (Baltimore, Md. : 1950)2025

Therapeutic potential of NRF2 activating drug RTA-408 in suppressing T cell effector responses and inflammatory bowel disease.

Debolina Dasgupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.